Home > Gastroenterology > ECCO 2020 > Head-to-Head Comparison of Treatments > Vedolizumab, adalimumab, and golimumab compared

Vedolizumab, adalimumab, and golimumab compared

Presented By
Dr F.S. Macaluso & Dr A. Casanotti
ECCO 2020
In real-life Italian data comparing clinical effectiveness of vedolizumab, adalimumab, and golimumab in ulcerative colitis (UC) patients, vedolizumab was superior to both anti-TNF agents in achieving clinical benefit at 52 weeks, and also in terms of treatment persistence [1]. The clinical endpoints were steroid-free clinical remission (partial Mayo score <2 without steroid use) and clinical response (reduction of the partial Mayo score ≥2 points with a concomitant decrease of steroid dosage compared with baseline). A total of 463 patients were included (vedolizumab, n=187; adalimumab, n=168; golimumab, n=108). Median follow-up was 47.6 weeks. After 8 weeks, a clinical benefit was achieved in 70.6%, 68.5%, and 67.6% of patients in the vedolizumab, adalimumab, and golimumab group, respectively. After 52 weeks, vedolizumab showed better rates of clinical benefit than adalimumab (71.6% vs 47.5; P<0.001) and golimumab (71.6% vs 40.2%; P<0.001);...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on